NDA 212905 · Verrica Pharms
Ycanth
Cantharidin · Topical
Last checked: Nov 19, 2026Latest source record: Jul 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jul 21, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
0 Phase 3, 0 recruiting
FAERS reports
183
33 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 13, 2024.
YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. ( 1 )
Mechanism: The mechanism of action of cantharidin in the treatment of molluscum contagiosum is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- YCANTH · CANTHARIDIN 0.7% · SOLUTION, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cantharidin" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum ContagiosumCompleted
Montefiore Medical CenterAcademic, hospital or other
NCT02665260 · 94 participants · Start Jul 2012 · Primary completion Nov 2015
Drug: Cantharidin; Placebo · For: Molluscum Contagiosum
North Idaho DermatologyAcademic, hospital or other
NCT01084824 · 70 participants · Start Jun 2007 · Primary completion Jun 2008
Drug: Liquid nitrogen and cantharidin; Liquid nitrogen and topical placebo · For: Verruca Vulgaris
Sites: Coeur d'Alene, Idaho
Queen Mary University of LondonAcademic, hospital or other
NCT01582321 · 56 participants (planned) · Start Mar 2012 · Primary completion Dec 2016
Drug: Typhoid vaccine; Cantharidin · For: Cardiovascular Function
Sites: London, United Kingdom
Queen Mary University of LondonAcademic, hospital or other
NCT05600062 · 48 participants · Start Mar 21, 2023 · Primary completion Feb 1, 2026
Drug: Racecadotril 100 milligram (MG) Oral Capsule; Placebo · For: Acute Respiratory Distress Syndrome
Sites: London, United Kingdom
GlaxoSmithKlineGSK (GSK)
NCT03426995 · 48 participants · Start Mar 13, 2018 · Primary completion May 2, 2019
Drug: Placebo; GSK3358699 and 2 more · For: Arthritis, Rheumatoid
Sites: Cambridge, United Kingdom
GlaxoSmithKlineGSK (GSK)
NCT01026064 · 44 participants · Start Jun 4, 2009 · Primary completion Nov 27, 2009
Drug: Azithromycin; Placebo · For: Inflammation
Sites: Cambridge, United Kingdom
GlaxoSmithKlineGSK (GSK)
NCT01762787 · 40 participants · Start Aug 17, 2010 · Primary completion Jan 14, 2011
Drug: Cantharidin solution; Aspirin and 3 more · For: Inflammation
Sites: Cambridge, United Kingdom
- Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and WomenActive, not recruiting
Queen Mary University of LondonAcademic, hospital or other
NCT05597098 · 34 participants (planned) · Start Dec 12, 2022 · Primary completion Dec 12, 2027
Drug: Cantharidin · For: Inflammation
Sites: London, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- application site vesicles78
- application site pain53
- blister30
- pain16
- application site burn12
- blister rupture8
- hypersensitivity8
- application site erythema7
- drug ineffective7
- accidental exposure to product6
- chemical burn6
- wrong technique in product usage process6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 5 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 9 |
| 2024 | 58 |
| 2025 | 59 |
| 2026 | 46 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ycanth (Cantharidin)
2024 spending
$15K
Beneficiaries
n/a
16 claims
Per beneficiary
n/a
$695.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $14,601 |
Part B: Ycanth (Cantharidin) · HCPCS J7354
2024 spending
$30K
Beneficiaries
16
27 claims
Per beneficiary
$1,898
2024 ASP limit $715.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $30,374 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical treatment for plantar warts: A systematic review.
García-Oreja S, Álvaro-Afonso FJ, García-Álvarez Y, et al. · Dermatol Ther 2021 · Systematic Review
- Topical treatments for cutaneous warts.
Kwok CS, Gibbs S, Bennett C, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Treatments for molluscum contagiosum: A systematic review.
Wang OJE, Shergill M, Saed Aldien A, et al. · J Dtsch Dermatol Ges 2026 · Systematic Review
- YCANTHTM (Cantharidin) Topical Solution.
Gupta AK, Mann A, Vincent K, et al. · Skinmed 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparative efficacy of treatments for molluscum contagiosum: A systematic review and network meta-analysis.
Chao YC, Ko MJ, Tsai WC, et al. · J Dtsch Dermatol Ges 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Bibliometric Analysis and Systemic Review of Cantharidin Research Worldwide.
He T, Duan C, Feng W, et al. · Curr Pharm Biotechnol 2024 · Systematic Review
Sponsor: Verrica Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.